62 day performance John Wayman North Cumbria. 62 Day performance 2012 (Upper GI)

Slides:



Advertisements
Similar presentations
Progress Against Stomach Cancer. 1980–1989 Progress Against Stomach Cancer 1980– : Combination chemotherapy improves outcomes for advanced stomach.
Advertisements

Implementing NICE guidance
One-stop dyspepsia clinic
WALES BOWEL CANCER AUDIT (WCBA) MDT DATA FOR PATIENTS DIAGNOSED AUGUST 2010-JULY 2011 YSBYTY GWYNEDD (YG) MDT.
Unit 14 Assessment Objective Three. Unit 14 Assessment Objective Three.
A Seamless Service..  Recognition that COPD and asthma a significant problem for our health economy  Data: 1800 admissions in 1996  1995: COPD and.
The Recovery Package Hayley Williams Macmillan Survivorship Programme Manager South Yorkshire Bassetlaw and North Derbyshire Dr Anthony Gore GP Cancer.
H. AlHussain, I. Busca, L. Eapen,, S. El-Sayed The Ottawa Hospital Cancer Center, University of Ottawa Department of Radiation Oncology.
Managing the patients experience of radical surgery with HIPEC for stage 4 colorectal disease Jackie Rodger Lead Colorectal Nurse Specialist Carol Baird.
Bowel Cancer Alex Hill. Why screen for bowel cancer?  Bowel cancer causes deaths per yr  It may be detected at asymptomatic stage by simple, safe.
Acute Oncology Service (AOS) Monday – Friday 8am – 4pm Bleep: 946 T: x5726 F: Dr Nicola Beech Dr Jillian Noble Dr Susannah.
Breast cancer patient pathway
How to manage suspected cancer
ACHIEVING THE CoC STANDARD FOR PSYCHOSOCIAL DISTRESS SCREENING Melissa Wright, LMSW, OSW-C Gilda’s Club of the Quad Cities Carma Herring, RN, MS, OCN Executive.
Radiology On-Call Dr. Ian Ross The University of Western Ontario.
NATIONAL CANCER PATIENT EXPERIENCE SURVEY REQUEST FROM LEAD CANCER NURSES: TO PUT THE NATIONAL CANCER PATIENT EXPERIENCE SURVEY RESULTS AND ACTIONS ON.
Acute Oncology Dr Nicola Storey.
The Role of the Radiology Nurse Senior Sisters Jill Harris & Carol Ewen 7 th November 2011.
TEMPLATE DESIGN © Acute abdominal pain in the emergency Gynaecology setting “what we have learnt ” Saadia Naeem, Rachana.
The Good, The Bad and The Patient Choice! Colorectal Patient Pathways Across the Network Presented by: Teresa Coombes Cancer, Oncology, Haematology and.
AUDIT OF DOWN-STAGING CHEMORADIATION FOR LOCALLY ADVANCED RECTAL CANCER DR J J NICOLL NORTH CUMBRIA UNIVERSITY HOSPITALS SEPTEMBER 2012.
Cancer Outcomes and Services Dataset Linda Wintersgill Information & Audit Manager, NECN.
MOQC Update Douglas Blayney, MD Physician Lead, MOQC Transforming Oncology Care Together.
Cancer and Nutrition Anna Clayton Community Nutritional Management Specialist Guildford and Waverley CCG Shaping healthcare for you.
Dr. Ian Ross Radiology On-Call. -12,000 cases / yr - CT >> US > MR - Clarify request - appropriateness - assess urgency (triage) - choose correct scan.
RESULTSOF UPPER GI MDT QUESTIONNAIRE Sukhbir Ubhi National Clinical Lead for Upper GI Cancer Services Collaborative 'Improvement Partnership'
LUCADA Jacqueline Brown Cancer Services Manager North Tees & Hartlepool Trust.
Radiology “Dos and Don’ts” Clinical Governance Medical Division 18 July 2013.
Care Coordination Patient Case 1.
National Oesophago–Gastric Cancer Audit  This slide set is designed to ◦Summarise the main audit findings for presentation at local MDT meetings.
Summary The National Clinical Pathway represents a pathway that is achievable now, requiring no extra resources but reliant on appropriate logistics. The.
Out of hours audit Jane Arthur Cancer Nursing Modernisation Manager NECN 26 th January 2011.
LUNG CANCER DR HUDA BADRI. OVERVIEW OF SESSION Learning objectives Quiz Tutorial on lung cancer and guidelines 15 minutes break Case studies 10minutes.
Straight to Test Colonoscopy Pilot Sas Banerjee, Matt Hanson, Aman Bhargava and Joseph Huang Consultant General & Colorectal Surgeons Noel Thin & Paul.
Gynaecological Oncology Patient Pathway Cecile Bergzoll Gynaecological Oncologist Wellington.
National Cancer Patient Experience Survey 2014 Uro-onc Clinical Nurse Specialist Action Plan - Jan 2015 SSG meeting Feb 2015.
Admissions of a non-admitted Access Policy Specialist Clinics Access Policy Implementation at Peter MacCallum Cancer Centre.
Value Stream Mapping. Tips Keep it high level Remember this is a value stream map NOT a process map Use approximately 8 process steps Focus on the high.
RCR Bladder Cancer Radiotherapy Audit 2016
National Optimal Clinical Pathway for suspected and confirmed lung cancer: Referral to treatment Note: this was previously circulated for discussion as.
Implementation of a lung health clinic in high-risk individuals in South East London: a prospective feasibility cohort study Background In 2013, lung cancer.
National Clinical Pathway for suspected and confirmed lung cancer:
SMDT SMDT SMDT Synchronous Metastasis on Staging/Surveillance
National Oesophago–Gastric Cancer Audit 2015.
Upper GI Cancer and Rehabilitation
Miriam Rigby Anthony Byrne Joanne Hayes Liz Hayles
Earlier diagnosis of lung cancer
The effect of neo-adjuvant chemotherapy on the discrepancy between the endoscopic ultrasonography (EUS) and pathological staging of oesophageal cancer.
CUP SSG May 2016 Dr Matt sephton
SWAG Cancer Alliance Update
Recognition and Referral of Suspected cancer NICE NG12 – 2Week Wait
Dorset County Hospital Cancer of Unknown Primary (CUP) Service
Pathway for patients with suspected Breast Cancer
Six stage journey When diagnosed with a brain tumour.
Management of Vulval Melanoma
Pathway for patients with suspected Skin Cancer
Pathway for patients with suspected Upper GI (OG) Cancer
Neuro Oncology Therapy Update
Pathway for patients with suspected colorectal cancer
National Oesophago-Gastric Cancer Audit 2018 Annual Report: Slide set
Lung Cancer Pathway Dr Heather Harris - Consultant Radiologist
Worcestershire Colorectal Cancer 2ww Pathway
Pathway for patients with suspected HPB Cancer Inter Provider Transfer
Upper GI SSG Meeting Statistics
General Anaesthetics & Diagnostic Imaging Pathway
Early and locally advanced breast cancer
Pathway for patients with suspected Breast Cancer
Airedale NHS Foundation Trust
Calderdale and Huddersfield NHS Foundation Trust
Presentation transcript:

62 day performance John Wayman North Cumbria

62 Day performance 2012 (Upper GI)

Upper GI Cancer pathway Triage of referral EndoscopyHistologyCTLocal MDTSpecialist MDT Further Investigation Neo-adjuvant chemotherapy

Upper GI Cancer pathway Triage of referral EndoscopyHistologyCTLocal MDTSpecialist MDT Further Investigation Neo-adjuvant chemotherapy 14 days

Upper GI Cancer pathway Triage of referral EndoscopyHistologyCTLocal MDTSpecialist MDT Further Investigation Neo-adjuvant chemotherapy 14 days

Upper GI Cancer pathway Triage of referral EndoscopyHistologyCTLocal MDTSpecialist MDT Further Investigation Neo-adjuvant chemotherapy 14 days

Upper GI Cancer pathway Triage of referral EndoscopyHistologyCTLocal MDTSpecialist MDT Further Investigation Neo-adjuvant chemotherapy 14 days 7 days

Upper GI Cancer pathway Triage of referral EndoscopyHistologyCTSpecialist MDT Further Investigation Neo-adjuvant chemotherapy 14 days 7 days

Upper GI Cancer pathway Triage of referral EndoscopyHistologyCTSpecialist MDT Further Investigation Neo-adjuvant chemotherapy 14 days 7 days

Upper GI Cancer pathway Triage of referral EndoscopyHistologyCTSpecialist MDT Further Investigation Neo-adjuvant chemotherapy 14 days 7 days

“Further Investigations” EUS (Newcastle)MDT PET CT (Preston)MDT Neck USS (NCUH)MDT CPEX fitness assessment (Newcastle) MDT Laparoscopy (Newcastle/NCUH) MDT

“Further Investigations” EUS (Newcastle)MDT PET CT (Preston)MDT Neck USS (NCUH)MDT CPEX fitness assessment (Newcastle) MDT Laparoscopy (Newcastle/NCUH) MDT <20days?

Why are we missing 62 day target? Nationally Long, multi-step pathway Diminishing performance of steps: “Step”“Pathway” 195%95% 295%90% 395%85% 495%80% Locally Limited capacity – CT – USS – MRI – Bronchoscopy – Endoscopy Reliance on other providers – EUS – C-PEX – PET CT – EMR

Saving time Solutions – >95% OGD within 7 days – >95% CT within 7 days – Investigate in parallel – Provide EUS and PET in house – Staging Admission – Remove MDT re-visits from pathway (Investigated to Protocol) Risks – Capacity? – Over investigation – Cost of equipment and expertise – Capacity? – Exclude specialist interpretation of results and insufficient CNS support to co-ordinate

Suggestions? Agree protocols for local MDT’s for – PET/Bone scan – EUS – Neck USS – Bronchoscopy – C-PEX Discuss at specialist MDT only after all investigation complete (or a result which “stops” the curative pathway) Combine investigations – EUS + Neck USS + C-PEX/Anaesthetic assessment Other Suggestion??